We answer the most frequently asked questions
Dendritic cell therapy is effective for all types of cancer, except for blood cancer. The method has existed since 2002 and its effectiveness has been proven in over 7000 scientific publications. DCT is usually possible at any point in the course of the disease. The earlier it is used, the better the chances of success, especially regarding the prevention of relapses.
Some types of leukemia - blood cancer - do not respond to DCT.
Many doctors have heard of it. However, the method has not yet made it into the international therapy guidelines for cancer treatment. The European Medicines Agency (EMA) allows its member states, under the responsibility and supervision of the respective health authorities, to grant licenses to qualified doctors, who must, however, have their own special clean room laboratory. In Europe, only Germany and some Baltic States make use of this permission.
DCT sometimes offers the possibility of avoiding chemotherapy, especially after surgical removal of the primary tumour. However, since there are standard therapies for most types of cancer, some of which have been developed over decades, it is often still advisable to use these therapies and to receive DCT as an additional therapy. It is known that tumour cells damaged by chemotherapy or radiation can be destroyed by immune cells much better than undamaged tumour cells, making a combination of these traditional cancer therapies and DCT favorable in many cases.
Yes, you can receive DCT in parallel to traditional chemotherapy or radiotherapy.
DCT can be applied at any stage of cancer. The outcome of DCT is, however, most promising when only small amounts of tumour cells are present, which is the case if the tumour is identified early or following surgical removal of a tumour. In an ideal early application, the aim is to keep the patient healthy - adjuvant therapy. We know that the immune system often functions much better in patients with a small tumour mass than in patients with a large tumour load. As with chemotherapy and radiotherapy, the earlier the therapy is started, the more successful it is.
In an already advanced situation, the aim is to alleviate the symptoms of the disease and to prolong the patient's life with a good quality of life - palliative therapy.
The safety of the dendritic cell vaccine is well established. The dendritic cells originate from the patient and are a natural component of their immune system. The only side effect that some patients experience is a small fever after the injection.
No, in fact DCT is often used to treat autoimmune diseases.
You will attend two appointments at our private clinic in Germany:
The first appointment - The blood collection. We will collect 200 ml of blood from you. The blood sample then goes directly to our clean room laboratory where our experts start the process of preparing your individual dendritic cell vaccination.
The duration of the visit is approximately two hours, involving a discussion with the doctor, examination, blood collection, and the administration of a high-dose vitamin C/D infusion which is included in the price.
The laboratory needs 6 days to produce the appropriate preparation from your cells.
The second appointment: Injection of the dendrites. This appointment takes place exactly one week after the blood collection. The duration of the appointment is approximately two hours, involving the administration of the injection under your skin. You will remain at the clinic for an observation period and receive one more cycle of high-dose vitamin C/D.
We recommend that you continue appointments with your own doctor to carry out regular check-ups and scans to monitor tumour mass.
Our patients report that they feel more energetic and better overall after just a few days. Measurable results, such as a decrease in tumour mass, can be seen after about 3 months.
The cost of dendritic cell therapy is EUR 18 250. A second cycle, which is rarely necessary, costs EUR 14 800.
This is different from country to country and will depend on your insurance status.
The treatment takes place in our private clinic in Germany.
In European countries, with the exception of Germany and some Baltic states, there is no approval for DCT by the respective health authorities yet. Additionally, the shipment of cells is considered illegal because no guarantee can be given for the effectiveness of the cells after transport.
The IASO Cancer Initiative was founded in 2018 by Bruno Rosset with the aim of improving success rates and quality of life for cancer patients worldwide by providing access to innovative, scientifically proven cancer therapies. These are often therapies that are not yet widely known or are only available in a few places in the world. So far, the network includes 8 innovative clinics, all specialized in integrated cancer care. The doctors are pioneers in cancer immunotherapy, e.g., dendritic cell therapy.
Iaso - Greek goddess of recovery, the healer.
Iaso is responsible for all processes of recovery, including cures, remedies and all paths leading to healing and complete health.
Her parents are Epione (soothing goddess) and the Greek god-physician Asclepios (Aesculap).
We are the pioneers of DCT with more than 20 years of experience in cell-based immunotherapies. We have our own Good Manufacturing Practice (GMP)-accredited clean room laboratory. We have conducted and published our own scientific studies.
We have all the necessary approvals, certifications, and authorizations from the German health authorities. We will be happy to send you a copy on request.
Our clinic works under specialist diagnosis and supervision by the well-known Paul Ehrlich Institute.
We are invested in guiding and supporting you personally in your decision to carry out DCT and throughout the process of your treatment.
Contact me directly to discuss any further questions you may have. I will reply to you within 24 hours.
E-mail: info@iaso-cancer.com
Phone: +41 81 330 73 73
Yes, of course. The first person of contact is often a family member, partner, or friend. I understand the position that you are in and can discuss and queries you may have with you.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". | |
cookielawinfo-checkbox-functional | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". | |
cookielawinfo-checkbox-necessary | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". | |
cookielawinfo-checkbox-others | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. | |
cookielawinfo-checkbox-performance | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". | |
viewed_cookie_policy | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |